Brokerages Set Insulet Co. (NASDAQ:PODD) PT at $272.81

Insulet Co. (NASDAQ:PODD) has been assigned an average rating of “Moderate Buy” from the sixteen analysts that are currently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $272.81.

A number of research firms have commented on PODD. Canaccord Genuity Group lifted their target price on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Citigroup boosted their price objective on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Barclays increased their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. BTIG Research boosted their price target on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Finally, Raymond James upped their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th.

Insulet Stock Down 1.0 %

PODD stock opened at $264.38 on Monday. The firm has a market cap of $18.54 billion, a PE ratio of 45.27, a PEG ratio of 4.12 and a beta of 1.22. Insulet has a one year low of $160.19 and a one year high of $279.77. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm’s 50 day moving average price is $265.09 and its 200-day moving average price is $231.39.

Insider Activity

In related news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.47% of the company’s stock.

Hedge Funds Weigh In On Insulet

Several hedge funds and other institutional investors have recently made changes to their positions in PODD. Blue Trust Inc. increased its stake in shares of Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 58 shares during the period. Venturi Wealth Management LLC grew its holdings in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 133 shares in the last quarter. Friedenthal Financial acquired a new position in Insulet during the 4th quarter worth approximately $57,000. TD Private Client Wealth LLC increased its position in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares during the last quarter. Finally, Versant Capital Management Inc raised its holdings in shares of Insulet by 106.1% in the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 157 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.